195 related articles for article (PubMed ID: 37151113)
1. Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Makharadze T; Quek RGW; Melkadze T; Gogishvili M; Ivanescu C; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Konidaris G; Rietschel P; Gullo G
Cancer; 2023 Jul; 129(14):2256-2265. PubMed ID: 37151113
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Gümüş M; Chen CI; Ivanescu C; Kilickap S; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Harnett J; Mastey V; Naumann U; Reaney M; Konidaris G; Sasane M; Brady KJS; Li S; Gullo G; Rietschel P; Sezer A
Cancer; 2023 Jan; 129(1):118-129. PubMed ID: 36308296
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
4. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Goldman JW; Garassino MC; Chen Y; Özgüroğlu M; Dvorkin M; Trukhin D; Statsenko G; Hotta K; Ji JH; Hochmair MJ; Voitko O; Havel L; Poltoratskiy A; Losonczy G; Reinmuth N; Patel N; Laud PJ; Shire N; Jiang H; Paz-Ares L
Lung Cancer; 2020 Nov; 149():46-52. PubMed ID: 32961445
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Medic N; Mann H; Shi X; Peters S; Mok T; Johnson M
Lung Cancer; 2023 Dec; 186():107422. PubMed ID: 37992595
[TBL] [Abstract][Full Text] [Related]
8. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Garon EB; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; Robinet G; Le Moulec S; Natale R; Schneider J; Shepherd FA; Garassino MC; Geater SL; Szekely ZP; Van Ngoc T; Liu F; Scheuring U; Patel N; Peters S; Rizvi NA
Clin Lung Cancer; 2021 Jul; 22(4):301-312.e8. PubMed ID: 33775558
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
[TBL] [Abstract][Full Text] [Related]
13. EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
Oaknin A; Monk BJ; Vergote I; Cristina de Melo A; Kim YM; Lisyanskaya AS; Samouëlian V; Kim HS; Gotovkin EA; Damian F; Chang CL; Takahashi S; Li J; Mathias M; Fury MG; Ivanescu C; Reaney M; LaFontaine PR; Lowy I; Harnett J; Chen CI; Tewari KS
Eur J Cancer; 2022 Oct; 174():299-309. PubMed ID: 35922251
[TBL] [Abstract][Full Text] [Related]
14. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
Hurvitz SA; Quek RGW; Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke E; Mina LA; Balmaña J; Fasching PA; Bhattacharyya H; Hannah AL; Robson ME; Wardley AM
Eur J Cancer; 2018 Nov; 104():160-168. PubMed ID: 30359909
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
[TBL] [Abstract][Full Text] [Related]
16. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S
Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
[TBL] [Abstract][Full Text] [Related]
20. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Gogishvili M; Melkadze T; Makharadze T; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Li S; McGuire K; Kaul M; Paccaly A; Quek RGW; Gao B; Seebach F; Weinreich DM; Yancopoulos GD; Lowy I; Gullo G; Rietschel P
Nat Med; 2022 Nov; 28(11):2374-2380. PubMed ID: 36008722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
